Working to facilitate rapid translation of scientific discoveries into therapeutics

Boris Minev

Boris Minev Photo cutted

Boris Minev, MD

Dr. Boris Minev has an extensive experience in immunotherapy of cancer, oncolytic virotherapy and cancer vaccine development. He is currently the Director of Immunotherapy and Translational Oncology at Genelux Corporation and holds a faculty appointment at the University of California – San Diego (UCSD). Dr. Minev graduated from The Medical Academy in Sofia, Bulgaria and worked at the National Cancer Center in Sofia. He then specialized in tumor immunology and vaccine development at the Weizmann Institute of Science, Israel, and more recently at the National Cancer Institute in Bethesda, Maryland, USA. Dr. Minev then joined the Moores UCSD Cancer Center and worked on the development of synthetic and recombinant vaccines for melanoma, breast cancer, prostate cancer, and brain tumors. He participated in numerous pre-clinical and translational projects related to the identification of new targets for immunotherapy of cancer, cytotoxic T cell immunity in patients with cancer, as well as on dendritic cell-based and nanotechnology-based vaccine development. Dr. Minev has worked extensively on stem cell biology and cancer stem cell targeting. He is recipient of the European Association of Cancer Research Fellowship, Fogarty International Fellowship and other awards. Dr. Minev has served on the Scientific Advisory Board of several biomedical companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others. In 2010, Dr. Minev joined Genelux Corporation where he is directing several translational and preclinical projects on oncolytic virotherapy, immunotherapy and nanotechnology.

2013-2021©European Society for Translational Medicine (EUSTM)